NEW YORK (GenomeWeb News) – Navigenics has reeled in $18 million in Series C financing from an investment round that included The Procter and Gamble Company, Kleiner Perkins Caufield and Byers, and Mohr Davidow Ventures.

The company plans to use the financing to continue researching ways genomics can be used in preventive health care and to "expand our clinical offerings into exciting new areas and lead the way in making personal genomics an integral part of employer-sponsored preventive health and wellness programs," Navigenics CEO and President Vance Vanier said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.